SWOT Analysis for Aarti Drugs Ltd. - Strengths

Add SWOT widget to your site/app

Mid-range Performer (DVM)

Rising Net Cash Flow and Cash from Operating activity

PEG lower than Industry PEG

Growth in Net Profit with increasing Profit Margin (QoQ)

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Company with Low Debt

Increasing profits every quarter for the past 2 quarters

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Book Value per share Improving for last 2 years

Company with Zero Promoter Pledge

Promoter decreasing their shareholding

Negative profit growth, promoters decreasing shareholding QoQ

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Inefficient use of capital to generate profits - RoCE declining in the last 2 years

Inefficient use of shareholder funds - ROE declining in the last 2 years

Degrowth in Revenue and Profit

Decline in Quarterly Net Profit (YoY)

Near 52 Week Low

Weak Momentum: Price below Short, Medium and Long Term Averages

Increasing Trend in Non-Core Income

RSI indicating price weakness

Top Losers

Near 52 Week Low

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

Street Favorite: High Analyst Rating with at least 20% upside

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Red Flag: Companies seeing significant coronavirus impact

Rising Delivery Percentage Compared to Prev Day

Average Affordability - Stocks with Medium Trendlyne Valuation Score versus Benchmarks

Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks